DarioHealth (DRIO) Competitors

$8.38 +0.28 (+3.40%)

Closing price 03:59 PM Eastern

Extended Trading

$8.20 -0.18 (-2.09%)

As of 04:10 PM Eastern

DRIO vs. SGHT, ELMD, LUCD, INFU, and CVRX

Should you buy DarioHealth stock or one of its competitors? MarketBeat compares DarioHealth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DarioHealth include Sight Sciences (SGHT), Electromed (ELMD), Lucid Diagnostics (LUCD), InfuSystem (INFU), and CVRx (CVRX). These companies are all part of the "medical equipment" industry.

How does DarioHealth compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Sight Sciences has higher revenue and earnings than DarioHealth. Sight Sciences is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.66	-$38.43M	-$0.71	N/A
DarioHealth	$22.36M	2.73	-$41.71M	-$10.43	N/A

In the previous week, DarioHealth had 5 more articles in the media than Sight Sciences. MarketBeat recorded 8 mentions for DarioHealth and 3 mentions for Sight Sciences. DarioHealth's average media sentiment score of 0.94 beat Sight Sciences' score of 0.57 indicating that DarioHealth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DarioHealth	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sight Sciences currently has a consensus price target of $8.31, indicating a potential upside of 59.86%. DarioHealth has a consensus price target of $35.00, indicating a potential upside of 317.91%. Given DarioHealth's higher possible upside, analysts clearly believe DarioHealth is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Sight Sciences has a net margin of -46.83% compared to DarioHealth's net margin of -192.23%. Sight Sciences' return on equity of -52.34% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
DarioHealth	-192.23%	-59.08%	-36.36%

Sight Sciences has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market. Comparatively, DarioHealth has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 30.9% of Sight Sciences shares are owned by company insiders. Comparatively, 3.5% of DarioHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Sight Sciences beats DarioHealth on 12 of the 16 factors compared between the two stocks.

How does DarioHealth compare to Electromed?

DarioHealth (NASDAQ:DRIO) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Electromed has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	2.73	-$41.71M	-$10.43	N/A
Electromed	$68.86M	4.39	$5.15M	$1.03	35.44

In the previous week, DarioHealth had 3 more articles in the media than Electromed. MarketBeat recorded 8 mentions for DarioHealth and 5 mentions for Electromed. DarioHealth's average media sentiment score of 0.94 beat Electromed's score of 0.45 indicating that DarioHealth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DarioHealth	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Electromed	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DarioHealth presently has a consensus price target of $35.00, indicating a potential upside of 317.91%. Electromed has a consensus price target of $37.50, indicating a potential upside of 2.74%. Given DarioHealth's higher probable upside, research analysts plainly believe DarioHealth is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Electromed has a net margin of 11.34% compared to DarioHealth's net margin of -192.23%. Electromed's return on equity of 15.71% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-59.08%	-36.36%
Electromed	11.34%	15.71%	13.37%

DarioHealth has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Electromed has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 40.8% of Electromed shares are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Comparatively, 10.5% of Electromed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Electromed beats DarioHealth on 12 of the 16 factors compared between the two stocks.

How does DarioHealth compare to Lucid Diagnostics?

DarioHealth (NASDAQ:DRIO) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Lucid Diagnostics had 1 more articles in the media than DarioHealth. MarketBeat recorded 9 mentions for Lucid Diagnostics and 8 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.94 beat Lucid Diagnostics' score of -0.33 indicating that DarioHealth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DarioHealth	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

DarioHealth presently has a consensus price target of $35.00, suggesting a potential upside of 317.91%. Lucid Diagnostics has a consensus price target of $4.13, suggesting a potential upside of 304.41%. Given DarioHealth's higher probable upside, research analysts clearly believe DarioHealth is more favorable than Lucid Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

DarioHealth has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	2.73	-$41.71M	-$10.43	N/A
Lucid Diagnostics	$4.71M	42.28	-$58.01M	-$0.96	N/A

DarioHealth has a net margin of -192.23% compared to Lucid Diagnostics' net margin of -1,426.27%. Lucid Diagnostics' return on equity of 0.00% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-59.08%	-36.36%
Lucid Diagnostics	-1,426.27%	N/A	-95.51%

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 3.5% of DarioHealth shares are held by company insiders. Comparatively, 6.8% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

DarioHealth has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Summary

Lucid Diagnostics beats DarioHealth on 9 of the 16 factors compared between the two stocks.

How does DarioHealth compare to InfuSystem?

DarioHealth (NASDAQ:DRIO) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, InfuSystem had 4 more articles in the media than DarioHealth. MarketBeat recorded 12 mentions for InfuSystem and 8 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.94 beat InfuSystem's score of 0.75 indicating that DarioHealth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DarioHealth	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InfuSystem	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DarioHealth presently has a consensus price target of $35.00, suggesting a potential upside of 317.91%. InfuSystem has a consensus price target of $15.00, suggesting a potential upside of 74.22%. Given DarioHealth's higher probable upside, research analysts clearly believe DarioHealth is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

InfuSystem has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	2.73	-$41.71M	-$10.43	N/A
InfuSystem	$142.40M	1.22	$870K	$0.38	22.66

InfuSystem has a net margin of 1.12% compared to DarioHealth's net margin of -192.23%. InfuSystem's return on equity of 2.78% beat DarioHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-59.08%	-36.36%
InfuSystem	1.12%	2.78%	1.41%

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 3.5% of DarioHealth shares are held by company insiders. Comparatively, 10.8% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

DarioHealth has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Summary

InfuSystem beats DarioHealth on 12 of the 15 factors compared between the two stocks.

How does DarioHealth compare to CVRx?

DarioHealth (NASDAQ:DRIO) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, CVRx had 7 more articles in the media than DarioHealth. MarketBeat recorded 15 mentions for CVRx and 8 mentions for DarioHealth. DarioHealth's average media sentiment score of 0.94 beat CVRx's score of 0.43 indicating that DarioHealth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DarioHealth	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CVRx	1 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

DarioHealth has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	2.73	-$41.71M	-$10.43	N/A
CVRx	$56.65M	2.69	-$53.31M	-$2.02	N/A

DarioHealth presently has a consensus price target of $35.00, suggesting a potential upside of 317.91%. CVRx has a consensus price target of $11.50, suggesting a potential upside of 100.35%. Given DarioHealth's higher probable upside, equities analysts clearly believe DarioHealth is more favorable than CVRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00

CVRx has a net margin of -89.14% compared to DarioHealth's net margin of -192.23%. DarioHealth's return on equity of -59.08% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-59.08%	-36.36%
CVRx	-89.14%	-120.76%	-48.38%

33.4% of DarioHealth shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 3.5% of DarioHealth shares are held by insiders. Comparatively, 13.9% of CVRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

DarioHealth has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, CVRx has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

Summary

DarioHealth beats CVRx on 9 of the 17 factors compared between the two stocks.

Get DarioHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRIO vs. The Competition

Export

Metric	DarioHealth	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$59.13M	$6.81B	$6.34B	$12.38B
Dividend Yield	N/A	1.74%	2.80%	5.35%
P/E Ratio	-0.94	50.22	20.90	25.61
Price / Sales	2.73	73.63	549.93	78.79
Price / Cash	N/A	24.26	43.26	56.33
Price / Book	0.83	6.61	9.93	6.96
Net Income	-$41.71M	$158.34M	$3.55B	$333.52M
7 Day Performance	4.04%	-2.49%	-0.33%	0.45%
1 Month Performance	10.78%	-1.90%	1.34%	4.06%
1 Year Performance	-36.55%	-1.85%	41.10%	36.24%

DarioHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRIO DarioHealth	2.8691 of 5 stars	$8.38 +3.4%	$35.00 +317.9%	-43.9%	$59.13M	$22.36M	N/A	200	News Coverage Earnings Report Gap Up
SGHT Sight Sciences	4.0179 of 5 stars	$4.24 +0.5%	$8.31 +95.9%	+43.3%	$230.93M	$77.36M	N/A	210	Analyst Downgrade Gap Up
ELMD Electromed	0.7275 of 5 stars	$25.82 +1.0%	$36.67 +42.0%	+49.1%	$214.90M	$68.86M	34.63	160	News Coverage Analyst Forecast Gap Up
LUCD Lucid Diagnostics	3.1066 of 5 stars	$1.09 -0.5%	$4.13 +280.2%	-14.3%	$210.87M	$4.71M	N/A	70	News Coverage
INFU InfuSystem	4.5205 of 5 stars	$10.27 -3.3%	$15.00 +46.1%	+42.8%	$207.88M	$143.44M	171.60	410	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRIO) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DarioHealth (DRIO) Competitors

DRIO vs. SGHT, ELMD, LUCD, INFU, and CVRX

How does DarioHealth compare to Sight Sciences?

Summary

How does DarioHealth compare to Electromed?

Summary

How does DarioHealth compare to Lucid Diagnostics?

Summary

How does DarioHealth compare to InfuSystem?

Summary

How does DarioHealth compare to CVRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRIO vs. The Competition

DarioHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DarioHealth (DRIO) Competitors

DRIO vs. SGHT, ELMD, LUCD, INFU, and CVRX

How does DarioHealth compare to Sight Sciences?

Which has higher earnings and valuation, SGHT or DRIO?

Does the media refer more to SGHT or DRIO?

Do analysts prefer SGHT or DRIO?

Is SGHT or DRIO more profitable?

Which has more risk and volatility, SGHT or DRIO?

Do institutionals & insiders believe in SGHT or DRIO?

Summary

How does DarioHealth compare to Electromed?

Which has better earnings and valuation, DRIO or ELMD?

Does the media prefer DRIO or ELMD?

Do analysts rate DRIO or ELMD?

Is DRIO or ELMD more profitable?

Which has more risk and volatility, DRIO or ELMD?

Do insiders and institutionals believe in DRIO or ELMD?

Summary

How does DarioHealth compare to Lucid Diagnostics?

Does the media refer more to DRIO or LUCD?

Do analysts prefer DRIO or LUCD?

Which has higher earnings & valuation, DRIO or LUCD?

Is DRIO or LUCD more profitable?

Do institutionals and insiders have more ownership in DRIO or LUCD?

Which has more volatility and risk, DRIO or LUCD?

Summary

How does DarioHealth compare to InfuSystem?

Does the media refer more to DRIO or INFU?

Do analysts prefer DRIO or INFU?

Which has higher earnings & valuation, DRIO or INFU?

Is DRIO or INFU more profitable?

Do institutionals and insiders have more ownership in DRIO or INFU?

Which has more volatility and risk, DRIO or INFU?

Summary

How does DarioHealth compare to CVRx?

Does the media prefer DRIO or CVRX?

Which has stronger earnings and valuation, DRIO or CVRX?

Do analysts prefer DRIO or CVRX?

Is DRIO or CVRX more profitable?

Do insiders & institutionals have more ownership in DRIO or CVRX?

Which has more volatility & risk, DRIO or CVRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRIO vs. The Competition

DarioHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools